ERBB2 and breast cancer: Similarly, a well described pooled analysis of five prospective clinical trials showed no significant impact of PIK3CA-mutation on the course of disease in patients with adequately treated HER2-positive BC, although the PIK3CA-mutated group had a significantly lower pCR rate [35].